Parallel Advisors LLC Has $39,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Parallel Advisors LLC trimmed its stake in Charles River Laboratories International, Inc. (NYSE:CRLFree Report) by 26.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 166 shares of the medical research company’s stock after selling 59 shares during the period. Parallel Advisors LLC’s holdings in Charles River Laboratories International were worth $39,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Nomura Asset Management Co. Ltd. increased its holdings in Charles River Laboratories International by 10.2% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 13,681 shares of the medical research company’s stock valued at $3,234,000 after purchasing an additional 1,261 shares during the period. Congress Wealth Management LLC DE grew its holdings in Charles River Laboratories International by 0.6% during the 4th quarter. Congress Wealth Management LLC DE now owns 53,816 shares of the medical research company’s stock worth $12,723,000 after acquiring an additional 302 shares during the period. GW&K Investment Management LLC grew its holdings in Charles River Laboratories International by 21.4% during the 4th quarter. GW&K Investment Management LLC now owns 55,510 shares of the medical research company’s stock worth $13,123,000 after acquiring an additional 9,782 shares during the period. Corient Private Wealth LLC grew its holdings in Charles River Laboratories International by 114.4% during the 4th quarter. Corient Private Wealth LLC now owns 13,358 shares of the medical research company’s stock worth $3,158,000 after acquiring an additional 7,127 shares during the period. Finally, Coldstream Capital Management Inc. acquired a new stake in Charles River Laboratories International during the 4th quarter worth about $418,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Trading Down 3.1 %

NYSE:CRL opened at $214.79 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.37 and a current ratio of 1.75. The firm has a market cap of $11.06 billion, a price-to-earnings ratio of 25.27, a price-to-earnings-growth ratio of 2.10 and a beta of 1.40. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $275.00. The firm has a 50-day moving average price of $231.10 and a two-hundred day moving average price of $231.31.

Charles River Laboratories International (NYSE:CRLGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, beating the consensus estimate of $2.05 by $0.22. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 11 earnings per share for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 1,304 shares of the stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $226.97, for a total value of $295,968.88. Following the completion of the sale, the executive vice president now owns 23,276 shares in the company, valued at approximately $5,282,953.72. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. UBS Group increased their price target on Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Robert W. Baird decreased their price target on Charles River Laboratories International from $282.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, May 10th. Mizuho started coverage on shares of Charles River Laboratories International in a research report on Friday. They set a “neutral” rating and a $235.00 price objective on the stock. TheStreet raised shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a research report on Friday, March 1st. Finally, StockNews.com raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Thursday. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $256.38.

View Our Latest Report on Charles River Laboratories International

Charles River Laboratories International Profile

(Free Report)

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

See Also

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLFree Report).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.